PDCD1 and renal cell carcinoma: In contrast, a subgroup analysis of the Checkmate-025 trial of RCC patients randomized to either anti-PD-1 monotherapy or everolimus showed that patients with bone metastases had an OS benefit with immune checkpoint inhibitors compared to everolimus (median OS 18.5 months vs. 13.8 months) supporting the use of immune checkpoint inhibitors for bone metastases (115).